Search

Your search keyword '"Berrino, Enrico"' showing total 282 results

Search Constraints

Start Over You searched for: Author "Berrino, Enrico" Remove constraint Author: "Berrino, Enrico"
282 results on '"Berrino, Enrico"'

Search Results

1. Correction to: Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres

2. Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

3. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue

6. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres

9. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma

10. Plasma microRNA ratios associated with breast cancer detection in a nested case–control study from a mammography screening cohort

12. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

13. Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.

14. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas

17. MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer

22. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.

23. Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer

24. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue

26. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update.

27. Alternative protocols of tissue fixation dramatically reduces the impact of DNA artifacts, unraveling the interpretation of clinical Comprehensive Genomic Profiling

28. Figure S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

29. Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

30. Supplementary Methods from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

31. Data from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

32. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

33. Abstract 6224: Exploring the integration of CMS subtyping and other omics in colorectal cancer classification and its reflection in stool miRNome and metagenome for non-invasive precision medicine

34. Figure S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

35. Table S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

36. Supplementary Data 3 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer

37. Supplementary Data 1 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer

38. Data from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer

39. uncropped western blot gels from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer

40. Supplementary Data 4 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer

41. Supplementary Data 2 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer

42. Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient

43. Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features

44. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance

45. Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)

46. HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

47. Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)

48. The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment

49. Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST

50. DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination

Catalog

Books, media, physical & digital resources